These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
174 related articles for article (PubMed ID: 12018630)
41. Paraoxonase (PON1) polymorphism & its relation with lipids in north west Indian Punjabis. Singh S; Verma M; Nain CK; Leelamma CO; Goel RC Indian J Med Res; 1999 Oct; 110():133-7. PubMed ID: 10645101 [TBL] [Abstract][Full Text] [Related]
42. Comparison of the ability of paraoxonases 1 and 3 to attenuate the in vitro oxidation of low-density lipoprotein and reduce macrophage oxidative stress. Liu Y; Mackness B; Mackness M Free Radic Biol Med; 2008 Sep; 45(6):743-8. PubMed ID: 18585453 [TBL] [Abstract][Full Text] [Related]
43. Serum paraoxonase activity in patients with type 1 diabetes compared to healthy controls. Mackness B; Durrington PN; Boulton AJ; Hine D; Mackness MI Eur J Clin Invest; 2002 Apr; 32(4):259-64. PubMed ID: 11952811 [TBL] [Abstract][Full Text] [Related]
44. Role of Paraoxonase 1 Activity and Oxidative/Antioxidative Stress Markers in Patients with Acute Cerebral Infarction. Zhu H; Zhao T; Liu J Clin Lab; 2018 Jun; 64(6):1049-1053. PubMed ID: 29945323 [TBL] [Abstract][Full Text] [Related]
45. Serum arylesterase/diazoxonase activity and genetic polymorphisms in patients with type 2 diabetes. Inoue M; Suehiro T; Nakamura T; Ikeda Y; Kumon Y; Hashimoto K Metabolism; 2000 Nov; 49(11):1400-5. PubMed ID: 11092501 [TBL] [Abstract][Full Text] [Related]
46. Antioxidant effect of atorvastatin is independent of PON1 gene T(-107)C, Q192R and L55M polymorphisms in hypercholesterolaemic patients. Sardo MA; Campo S; Bonaiuto M; Bonaiuto A; Saitta C; Trimarchi G; Castaldo M; Bitto A; Cinquegrani M; Saitta A Curr Med Res Opin; 2005 May; 21(5):777-84. PubMed ID: 15969877 [TBL] [Abstract][Full Text] [Related]
47. Levels of asymmetric dimethylarginine, nitric oxide and lipid peroxidation markers in patients with end-stage renal disease having peritoneal dialysis treatment. Göçmen AY; Sahin E; Koçak H; Tuncer M; Gümüşlü S Clin Biochem; 2008 Jul; 41(10-11):836-40. PubMed ID: 18457672 [TBL] [Abstract][Full Text] [Related]
48. HDL3-related decreased serum paraoxonase (PON) activity in uremic patients: comparison with the PON1 allele polymorphism. Schiavon R; Battaglia P; De Fanti E; Fasolin A; Biasioli S; Targa L; Guidi G Clin Chim Acta; 2002 Oct; 324(1-2):39-44. PubMed ID: 12204423 [TBL] [Abstract][Full Text] [Related]
49. LDL density and oxidation are modulated by PON1 promoter genotype in patients with Alzheimer's disease. Cagnin A; Leon A; Vianello D; Colavito D; Favaretto S; Zarantonello G; Stecca A; Ermani M; Zambon A J Alzheimers Dis; 2013; 34(2):377-85. PubMed ID: 23207490 [TBL] [Abstract][Full Text] [Related]
50. Serum cystatin C is a determinant of paraoxonase activity in hemodialyzed and renal transplanted patients. Varga E; Seres I; Harangi M; Sztanek F; Asztalos L; Lõcsey L; Borbás B; Szegedi J; Kárpáti I; Paragh G Dis Markers; 2009; 26(3):141-8. PubMed ID: 19597297 [TBL] [Abstract][Full Text] [Related]
51. Synergistic effects of BuChE non-UU phenotype and paraoxonase (PON1) 55 M allele on the risk of systemic lupus erythematosus: influence on lipid and lipoprotein metabolism and oxidative stress, preliminary report. Bahrehmand F; Vaisi-Raygani A; Rahimi Z; Ahmadi R; Kiani A; Tavilani H; Vaisi-Raygani H; Pourmotabbed T Lupus; 2014 Mar; 23(3):263-72. PubMed ID: 24399815 [TBL] [Abstract][Full Text] [Related]
52. The effect of meals rich in thermally stressed olive and safflower oils on postprandial serum paraoxonase activity in patients with diabetes. Wallace AJ; Sutherland WH; Mann JI; Williams SM Eur J Clin Nutr; 2001 Nov; 55(11):951-8. PubMed ID: 11641743 [TBL] [Abstract][Full Text] [Related]
53. Human apolipoprotein A-II enrichment displaces paraoxonase from HDL and impairs its antioxidant properties: a new mechanism linking HDL protein composition and antiatherogenic potential. Ribas V; Sánchez-Quesada JL; Antón R; Camacho M; Julve J; Escolà-Gil JC; Vila L; Ordóñez-Llanos J; Blanco-Vaca F Circ Res; 2004 Oct; 95(8):789-97. PubMed ID: 15388641 [TBL] [Abstract][Full Text] [Related]
54. Assessment of the relationship between serum paraoxonase activity and epicardial adipose tissue in hemodialysis patients. Abdallah E; El-Shishtawy S; Sherif N; Ali A; El-Bendary O Int Urol Nephrol; 2017 Feb; 49(2):329-335. PubMed ID: 27878751 [TBL] [Abstract][Full Text] [Related]
55. Interaction of paraoxonase-192 polymorphism with low HDL-cholesterol in coronary artery disease risk. Mendonça MI; Dos Reis RP; Freitas AI; Pereira A; Sousa AC; Freitas S; Ornelas I; Freitas C; Brehm A; Araújo JJ Rev Port Cardiol; 2010 Apr; 29(4):571-80. PubMed ID: 20734577 [TBL] [Abstract][Full Text] [Related]
56. Metabolic syndrome in children with chronic kidney disease: PON1 and treatment modality. Gómez-Díaz RA; García-Bello JA; Mondragón-González R; Díaz-Flores M; Valladares-Salgado A; Gallardo JM; Talavera JO; Wacher NH Arch Med Res; 2013 Nov; 44(8):645-9. PubMed ID: 24211756 [TBL] [Abstract][Full Text] [Related]
57. Plasma paraoxonase 1 arylesterase activity in D-galactose-induced aged rat model: correlation with LDL oxidation and redox status. Kumar D; Rizvi SI Aging Clin Exp Res; 2014 Jun; 26(3):261-7. PubMed ID: 24214524 [TBL] [Abstract][Full Text] [Related]
58. Human plasma paraoxonase 1 (PON1) arylesterase activity during aging: correlation with susceptibility of LDL oxidation. Mehdi MM; Rizvi SI Arch Med Res; 2012 Aug; 43(6):438-43. PubMed ID: 22959975 [TBL] [Abstract][Full Text] [Related]
59. Paraoxonase-1 concentrations in end-stage renal disease patients increase after hemodialysis: correlation with low molecular AGE adduct clearance. Gugliucci A; Mehlhaff K; Kinugasa E; Ogata H; Hermo R; Schulze J; Kimura S Clin Chim Acta; 2007 Feb; 377(1-2):213-20. PubMed ID: 17118352 [TBL] [Abstract][Full Text] [Related]